Idera Pharmaceuticals,Inc. (NASDAQ:IDRA) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

Idera Pharmaceuticals,Inc. (NASDAQ:IDRA) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition

On October24, 2017,Idera Pharmaceuticals,Inc. (the “Company”) filed a prospectus supplement with the Securities and Exchange Commission in connection with a proposed offering of shares of its common stock, as described in the press release filed under Item 2.02 of this Current Report on Form8-K, that included estimated information about the Company’s cash, cash equivalents and investments as of September30, 2017. As of September30, 2017, the Company estimates its cash, cash equivalents and investments was approximately $65.3 million. This estimate was prepared by management in good faith based upon internal reporting and expectations as of and for the three months ended September30, 2017. This estimate is preliminary, and unaudited, and may be revised as a result of management’s further review of the Company’s results. The Company and its auditors have not completed the normal quarterly review procedures as of and for the period ended September30, 2017, and there can be no assurance that the Company’s final results for this quarterly period will not differ from this estimate.

The information in this Item 2.02 of this Current Report on Form8-K shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 2.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October24, 2017, Mr.Youssef El Zein resigned from the Board of Directors of the Company (the “Board”), effective immediately. Mr.El Zein’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Item 2.02. Other Events.

On October24, 2017, the Company issued a press release announcing its intention to offer and sell $60 million of shares of its common stock in an underwritten public offering, subject to market conditions and other factors, to the Company’s effective Registration Statement on FormS-3 (File No.333-219851). The full text of the press release issued in connection with the announcement is attached to this Current Report on Form8-K as Exhibit99.1 and is incorporated herein by reference.

Item 2.02. Financial Statements and Exhibits.

Exhibit No.

Description

99.1

Press Release dated October24, 2017


IDERA PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a17-19042_7ex99d1.htm EX-99.1 Exhibit 99.1     Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock   CAMBRIDGE,…
To view the full exhibit click here

About Idera Pharmaceuticals,Inc. (NASDAQ:IDRA)

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company’s TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.